DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pegaspargase
Pegaspargase
BC Cancer Benefit Drug List September 2021
Australian Public Assessment Report for Pegaspargase
Acute Lymphoblastic Leukaemia: ALL06 Schema
Oncaspar, INN-Pegaspargase
Prescribing Information | VELCADE® (Bortezomib)
Acute Lymphoblastic Leukemia (ALL) (Part 1 Of
Negative Change Add Inclusion Criteria
Standard Oncology Criteria C16154-A
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
Velcade® (Bortezomib)
Overview of the Current Treatment Strategy in Extranodal NK/T-Cell Lymphoma: from Diagnosis to Recurrence
Evaluation of Immunologic Crossreaction of Antiasparaginase Antibodies in Acute Lymphoblastic Leukemia (ALL) and Lymphoma Patien
Haematologica August 2021
Cancer Drug Costs for a Month of Treatment at Initial Food
Proposal for the Inclusion of PEG-E Coli Asparaginase in the WHO Model List of ESSENTIAL MEDICINES for the Treatment of Acute Lymphoblastic Leukemia
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2010
Asparaginase
Oncaspar (Pegaspargase) Injection, for Intramuscular Or Intravenous ® Use • History of Serious Allergic Reactions to Oncaspar (4) Initial U.S
Top View
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Pegaspargase (Oncaspar)
Pegaspargase (Oncaspar) for Acute Lymphoblastic Leukaemia
How to Order Chemotherapy at Shands at the University of Florida - Inpatient
List Item Oncaspar : EPAR
Chemical Compatibility of Chemoclave™ and Chemolock™
NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2014
Hemodialysis Drug Removal
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Oncology Agents Not Listed in Seer Book 8
Appendix B. Drug Codes Requiring Authorization the Following Codes Will Require Authorization for MA Effective Oct 1, 2017 Page
A New Asparaginase for Acute Lymphoblastic Leukemia
34293 COVID Vaccine Clinicia
LYASPMEDEX Protocol
Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
AHFS Pharmacologic-Therapeutic Classification System
2020 Table of Drugs
Auspar Attachment 1: Product Information for Pegaspargase
Current Drug Research on Pegylation with Small Molecular Agents
Cancer Drug Costs for a Month of Treatment at Initial Food and Drug Administration Approval
Year of FDA Monthly Cost Approval
NIOSH Alert: Preventing Occupational Exposures to Antineoplastic
June MPU WV FINAL 2017.Docx
Do Not Tube List
Asparaginase Dosing, Monitoring, and Toxicity Management – Adult/Pediatric – Inpatient/Ambulatory Clinical Practice Guideline
The Cost-Effectiveness of Pegaspargase Versus Native Asparaginase for First-Line Treatment of Acute Lymphoblastic Leukaemia
Velcade Pediatric Postmarketing Pharmacovigilance Review
Asparaginase-Induced Hepatotoxicity: Rapid Development of Cholestasis
Hypersensitivity Rates in Pediatric Patients Receiving Intravenous Or Intramuscular Asparaginase Agents
Supplementary Online Content
Chemotherapy Agents Used During Treatment
Hazardous Drug List
Regimen Reference Order – LEUK – ALC6 (Interim Maintenance)
Renal Impairment Hepatic Impairment Agent PK Summary Available
Medications That Are Considered Hazardous
Envolve Pharmacy Solutions Criteria Working Template ACCESSIBLE
Pegaspargase (Oncaspar), Calaspargase Pegol-Mknl (Asparlas)
BC CANCER CHEMOTHERAPY PREPARATION and STABILITY CHART DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative
Antineoplastic Drugs